Top 6 Malpractice Consult articles of 2019
Here are the six most-read “Malpractice Consult” columns of 2019 from Brianne Goodwin, JD, RN, and Acacia Brush Perko, Esq.
Related Articles
Dr. Daniel Carson on telehealth vs in-person urology visits
“Patient-reported satisfaction scores were high for both telehealth and inpatient visits for both new and established encounters,” says Daniel Carson, MD, MS.
sNDA submitted to FDA for darolutamide plus ADT in mHSPC
“Patients in the darolutamide arm did not reach first [radiological progression-free survival] median, but at 24 months, 70[.3]% had not progressed vs 52[.1]% in the…
Device-related problems and event rates for PEG hydrogel spacers appear low
The overall report rate per unit sold of the PEG hydrogel spacers was 0.40%.
Investigators evaluate patient preferences on in-person vs telehealth urology visits
“I would say the take-home message is that we found that from a patient-centered orientation, telehealth for new and established patients have comparably high satisfaction…
Study to compare TLX250-CDx vs contrast-enhanced CT for recurrent ccRCC
“We are pleased that a first patient has been imaged in the CA-NINE trial, which supports potential label expansion for TLX250-CDx into recurrent, metastatic disease,”…
Ra223 plus SABR does not delay progression of oligometastatic HSPC
“The addition of radium-223 to SABR metastasis-directed therapy in low-volume bone-metastatic hormone-sensitive prostate cancer does not delay progression of disease in the RAVENS study,” said…
Phase 3 trial launches of UGN-103 in low-grade, intermediate-risk NMIBC
In total, the phase 3 UTOPIA trial plans to enroll 87 patients with LG-IR-NMIBC to assess the safety and efficacy of UGN-103.
MIRAGE trial: Margin reduction with MRI-guided SBRT reduces toxicity vs CT-guided SBRT
“The toxicity benefits of aggressive margin reduction persist beyond the acute phase post-SBRT,” the authors wrote.
Alexander Pastuszak, MD, PhD: Is hormone therapy safe after prostate cancer radiotherapy?
Pastuszak discusses the evolving nature of understanding how testosterone therapy post-radiation for prostate cancer may beneficial or harmful to patients, and how to navigate the…
Refining prostate cancer therapy strategy to address RAPTOR findings
Soumyajit Roy, MS, MBBS, explains how findings showing 5-year biochemical recurrence status may predict prostate cancer cure should alter the clinician-patient interaction.